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Results of a controlled drug trial in membranoproliferative glomerulo.
nephritis. A prospective randomized drug trial was carried out on 59
patients with confirmed membranoproliferative glomerulonephritis
(MPGN). The treatment group (27 patients) received cyclophospha-
mide, coumadin, and dipyridamole for 18 months, and the control group
(32 patients) received no specific therapy. Complications of the renal
disease such as hypertension and fluid retention were treated similarly
in both groups. Entrance criteria included confirmed renal pathology
demonstrating either types I or II MPGN, a corrected creatinine
clearance (Car) of less than 80 mllmin/1 .73 m, and/or proteinuria
greater than 2 g/day. Actuarial survival was not different between the
treatment and the control groups in either MPGN type and was 85% in
type I and 90% in type II at 2 years. The change in renal function, as
measured by both the slope of Ccr and the plasma creatinine reciprocal
(1/Cr) at 6, 12, and 18 months was not significantly different between
treatment and control groups in either types I or II when tested by both
parametric and nonparametric analysis. The age, sex, and initial level of
Ccr did not influence the rate of decline. Control and treatment group
proteinuria was not different at any time point in either types I or II
MPGN. The small numbers of type II MPGN cases do not give
sufficient power to allow conclusions regarding this therapy in type II.
We can conclude that this treatment is ineffective in altering the natural
history of type I MPGN.
Résultats d'un essai médicamenteux contrôlé dans Ia glomérulonephrite
membrano-proliférative. Un essai médicamenteux prospectifrandomisé
a été entrepris chez 59 malades atteints de glomérulondphrite
membrano-proliférative confirmde (MPGN). Le groupe traité (27
malades) a recu de la cyclophosphamide, de Ia coumadine et du
dipyridamole pendant 18 mois, et le groupe contrOle (32 malades) n'a
pas recu de traitement specifique. Les complications de Ia néphropathie
telles que l'hypertension et al retention liquidinne ont Cté traitées de
facon identique dans les deux groupes. Les critéres d'inclusion
comprenaient une histologierenale confirmCe ddmontrant une MPGN
de type I ou de type II, une clearance de Ia créatinine corrigCe (Ccr) de
moms de 80 ml/min/1 ,73 m2 et/ou une protéinurie de plus de 2 g/jour. La
survie actuarielle ne différait pas entre les groupes traité et contrôle
dans aucun des types de MPGN, et était de 85% dans le type I et de 90%
dans le type II a 2 ans. La modification de Ia fonction rénale, mesurée
a la fois par la pente de CC. et par I'inverse de Ia créatininémie (1/Cr) a
6, 12, et 18 mois n'était pas significativement différente entre les
groupes traité et contrôle, dans les types I ou II, paranalyse
paramétrique et non paramétrique. L'fige, le sexe, et le niveau initial de
Ia C. n'influencaient pas la vitesse du ddclin. La protéinurie des
groupes contrôleet traité ne différait pas a aucun moment dans les
MPGN de types I ou II. Le petit nombre de cas de MPGN de type II ne
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donnait pas une puissance suffisante pour permettre des conclusions en
cc qui concerne ce traitement dans le type II. Nous pouvons conclure
que ce traitement est incapable d'altérer l'histoire naturelle de la MPGN
de type I.
Glomerulonephritis remains the commonest recognized
cause of endstage renal disease in both adults [1, 2] and children
[31; membranoproliferative glomerulonephritis (MPGN) is the
type most frequently documented that results in terminal renal
failure [4]. The natural history and clinical pathological correla-
tions in MPGN have been known for several years and have
been recently reviewed [5—7]. Because pathological classifica-
tion has changed, we now classify MPGN into types I and II
[8—12]. Habib et al [13, 141 showed a 50% statistical mortality
between 9 and 10 years in types I and II when all patients with
crescents were excluded. Kincaid-Smith [15] and other inves-
tigators [13, 14, 16] subsequently demonstrated a much worse
prognosis with only a 30% 3-year survival once the patients had
significant proteinuria or a reduced creatinine clearance. Other
features which may indicate a worse prognosis include the early
age of onset of the disease, acute nephritic presentation,
hypertension, and the presence of crescents on renal biopsy.
Microscopic and/or macroscopic hematuria do not seem rel-
evant to prognosis [11—16]. The complement component, C3,
may be depressed in both types of MPGN, but the literature
varies whether or not its level has any prognostic value [13, 14,
17—21].
The effects of various forms of therapy, including indometh-
acm [22], prednisone [23—25], and indomethacin combined with
cyclophosphamide [26], on the outcome of this type of glomeru-
lonephritis have been variable and difficult to interpret because
of the absence of suitable control subjects and the small number
of patients in the published papers. Recently, Donadio and
Holley [6] and Donadio et a! [27] suggested that a combination
of aspirin and dipyridamole may be effective. The most dra-
matic published results were by Kincaid-Smith [28] who dem-
onstrated a very significant improvement in kidney survival in a
small uncontrolled trial in severely affected patients treated
with a combination of cyclophosphamide, coumadin, and
dipyridamole. Since 1975, the Metropolitan Toronto Glomeru-
lonephi-itis Registry [29] has been conducting a randomized
prospective drug trial to compare the effects of this drug
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combination versus no specific therapy in a similarly affected
group of patients with types I or II MPGN.
Methods
Trial entrance criteria included a renal biopsy specimen with
a minimum of eight different glomeruli demonstrable, taken
within 12 months of trial entry and of sufficient size to allow
examination by light, immunofluorescent, and electron micros-
copy. Although a single nephropathologist's diagnosis of
MPGN was sufficient to include the patient, quarterly meetings
of all involved pathologists reviewed the material to confirm the
initial impression. Previously established criteria were used to
classify this tissue into types I or II [7, 9, 12, 13]. All patients
with crescents were excluded. All patients entered also had to
demonstrate proteinuria greater than 2 g/day and/or a corrected
endogenous creatinine clearance (Ccr) of less than 80 mI/mm.
Secondary causes of MPGN were ruled out and only idiopathic
cases were entered.
Other exclusion criteria included active infection, previous
tuberculosis, a history of radiological evidence of peptic ulcer
disease, and uncontrolled hypertension (diastolic greater than
110 mm Hg despite therapy). The study was approved by the
University of Toronto Human Ethics Committee, and all pa-
tients were entered only after an informed consent was signed.
No specific immunosuppressive drug, steroids, antiplatelet
agents, or anticoagulants were allowed within 6 months of trial
entry.
The physicians called the Glomerulonephritis Registry [29]
after the patient consented to the trial. The registrars then
stratified the patients into types I or II MPGN and assigned the
patients to either the treatment (T) or control (C) groups. The
clinical and laboratory followup was a minimum of once per
month for 6 months and every 2 months for the subsequent 12
months.
Cyclophosphamide dosage was 1.5 to 2.0 mg/kg. If the
absolute white cell count fell below 3,000 cu/ml, the dose was
reduced.
Dipyridamole was started at 25 mg q.i.d. and increased by
100 mg124 hr weekly, until the full dose of 100 mg q.i.d. was
reached.
Coumadin was given as a single daily dose and adjusted to
maintain the one step prothrombin 2 to 2.5 times the control
value.
Blood pressure and edema were controlled by diuretics
and/or antihypertensive agent(s) of the physician's choice, but
the diastolic pressure was to be maintained at less than 100 mm
Hg in the sitting position.
A standard history and physical examination were recorded
at each visit [29]. Routine laboratory tests included endogenous
creatinine clearance (corrected for surface area), 24-hr protein-
uria, plasma creatinine, electrolytes and uric acid, blood urea
nitrogen, hemoglobin, hematocrit, white cell count and dif-
ferential, platelet count, and complete urinalysis.
The trial was for 18 months unless one of the following stop
points was reached:
(1) Cerebral hemorrhage; (2) significant gastrointestinal hem-
orrhage, that is, any overt melena or hematemesis or covert
bleeding as demonstrated by unexplained hemoglobin decrease
greater than 2 g/dl; (3) recurrent bleeding into the urinary tract,
skin, or muscle with a fall in hemoglobin greater than 2 gldl
(When a single acute episode of bleeding occurred, the
anticoagulants and antiplatelet agents were to be discontinued
but the trial could be re-instituted if no active bleeding point
was determined and the source was either gastrointestinal or
genitourinary.); (4) sustained diastolic pressure greater than 110
mm Hg despite vigorous antihypertensive therapy; (5) a
leukocyte count less than 3,000/m13 repeated, platelet count less
than 60,000/m13, biirubin greater than 1.5 mgldl, or persistent
nausea.
Cyclophosphamide was temporarily discontinued if any of
these parameters were reached and then restarted at 50% of the
previous dose and adjusted according to the symptoms and/or
laboratory values. If any or all of the symptoms reoccurred at
this lower dose, the trial was discontinued.
(6) Progression of the renal disease: If the plasma creatinine
increased by more than 5 mg/dl from the initial value or reached
a value more than 10 mgldl (corrected Ccr less than 10 mllmin),
the trial was to be discontinued. (7) During any acute systemic
illness, the physician could decrease or discontinue any or all
medications. The therapy was to be reinstituted once the acute
infection cleared.
Statistical analysis
Data were collected on a standardized form [29]. The data
management and statistical analysis were carried out using the
statistical analysis system (SAS) [30]. Each patient had a slope
calculated using the information derived from the endogenous
Cr and the time interval between each visit at 6, 12, and 18
months after trial entry. Another set of slopes was derived
applying the same method but using the reciprocal of the plasma
creatinine against time. The 24-hr protein excretions were
assessed on each patient at 6, 12, and 18 months. Analyses were
made on the total treatment and control group and again after
separation into types I and II treatment and control.
Analysis of variance was used to compare the response
variables, Ccr and 1/Cr, between the treatment and control
groups, adjusting for disease type and sex. Analysis of covari-
ance allowed adjustments for age, severity of initial proteinuria,
and initial Cc. level. Treatment and control groups were com-
pared both with the Student's t test and the more robust
Mann-Whitney test. For all analyses, two-tailed P values are
reported.
Results
Seventy-five patients were clinically assessed, although only
64 were deemed pathologically and clinically acceptable, and
were willing to participate in the study. Three patients were
excluded from subsequent analysis because of drug intolerance
within 3 weeks of trial entry. Two other patients were excluded
because they reached a Cr of less than 10 mllmin within I
month of trial entry (one patient in the control group and one
patient in the treatment group). All reported analyses were done
on the remaining 59 patients, 27 T and 32 C. In the type I group,
there were 23 males (15 C, 8 T), 24 females (10 C, 14 T), and in
the type II group there were 7 males (4 C, 3 T) and 5 females (3
C, 2 T). The incidence of hypertension at presentation was
similar in both groups, 41% T and 48% C. Patient clinical and
laboratory profiles at trial entry in the T and C groups are
outlined in Table I. The mean slopes of the corrected creatinine
clearance in the C and T group in types I and II at 6, 12, and 18
438 Cattran et a!
Table 1. Patient profile at trial entry
Table 2. Change in corrected creatinine clearance, ml/min/yeara
MPGN type Group
Months
6 12 18
—8
0
=0.4
I Control
Treatment
9.5
—5
P=0.5
—4
—6
=0.9
11 Control
Treatment
—31
—31
P=0.9
17
—18
=0.3
—1
—14
—0.5
a The values at 6, 12, and 18 months represent the mean change in C.
ineach group and type studied. The P values reported are the standard
two-tailed (tests based on means, but tests were also performed using
the Mann-Whitney test (Wilcoxan two-sample test) with again no
statistical difference seen between the control and treatment groups in
either types I or II MPGN.
months are illustrated in Table 2. There was no statistical
difference by either Student's t test or Mann-Whitney between
the C and T group in either types I or II MPGN. The slope or
change from the initial CC. as defined by "zero" to the final Cr
at 18 months is depicted for each individual patient in the T and
C groups for types I and II in Figures 1 and 2. Analysis of the
slopes created from the reciprocal of the plasma creatinine
versus time also showed no statistical difference between
groups in either type of MPGN. Mean daily proteinuria at 6, 12,
and 18 months is outlined in Table 3. Statistical analysis showed
no difference between the groups in either types I or II by
Student's t test or by Mann-Whitney. Analysis of covariance
was then used to compare the mean difference in these two
variables, that is, Cr, and the reciprocal of plasma creatinine in
the types I and II treatment and control groups. This analysis
adjusted for differences between the two groups in terms of age
at trial entry, sex, initial creatinine clearance, and initial pro-
teinuria. None of these factors proved to be of independent
significance in either types I or II nor were they responsible for
the lack of difference found between the treatment and control
groups. Variations in the slopes of creatinine clearance over the
18-month period in each patient related to both age and to initial
Treatment Control
Fig. 1. The slope (points) or change from "0" in creatinine clearance
(Cc,) during the 18-month study in the type I MPGN patients. The start
of the slope was the initial C. in each patient. In the treatment group,
the mean change in Ccr at 18 months was 0 mI/min/! .73 m2 while in the
control group the mean change in C. was —9 mI/mm/i .73 m2. This was
of no statistical significance (P> 0.4).
creatinine clearance in both types of MPGN is graphically
illustrated in Figures 3 and 4.
All patients, once included in the treatment group, were
assumed to remain on the medications until the final analysis
(Table 2). Six patients did not complete the full 18 months of
triple therapy, mostly because of drug complications. A list of
major and minor drug-related problems is given in Table 4.
The statistical analysis was repeated on those patients who
completed the full 18 months of treatment (type I, 17 patients;
type II, 4 patients). The mean slope of the CCr at 18 months in
this treatment group, type I, was —3 ml/min/year versus control
—8 mllminlyear (Mann-Whitney P > 0.7) and treatment group,
type II — 16 mllminlyear versus control — 1 ml/min/year (Mann-
Whitney P> 0.3).
Group
Control (N = 25) Treatment (N = 22)
Mean Range Mean Range
MPGN type I
Earliest known renal abnormality, years 33 (4.5 to 70) 37,5 (11 to 77)
Age at trial entry, years 34 (6 to 70) 38 (12 to 77)
Initial creatinine clearance, ml/min/1.73 m2 64 (18 to 135) 65 (16 to 113)
Initial plasma creatinine, mg/dl 1.8 (0.7 to 7.0) 1.7 (0.7 to 5.9)
Proteinuria, gm/day 5.2 (0.85 to 16.4) 3.6 (0.4 to 8.3)
MPGNtypeII (N = 7) (N = 5)
Earliest known renal abnormality, years 16.5 (4 to 57) 17.5 (6 to 26)
Age at trial entry, years 19 (7 to 58) 19.7 (6 to 28)
Initial creatinine clearance, mi/mm/I .73 m2 87 (51 to 131) 63 (37 to 115)
Initial plasmt creatinine, mg/dl 0.9 (0.3 to 1.2) 1.2 (0.7 to 2.1)
Proteinuria, g/day 4.3 (0.1 to 11.7) 6.8 (1.7 to 12.8)
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Treatment Control
Fig. 2. The slope (points) or change from '0" in creatinine clearance
(Ce,.) during the 18-month study in the type II MPGN patients. The start
of the slope was the initial Ccr in each patient. The mean change in Ccr
was — 14 mI/mm/i .73 m2 in the treatment group versus a change of + 1
ml/min/l.73 m2 in the control group. This was of no statistical signifi-
cance (P 0.5).
- 0 •00
•
Age, years
0
MPGN type Group
Number of months
6 12 18
I Control
Treatment
4.9
4.4
P=0.6
4.8
4.2
=0.2
4.2
3.5
=0.6
II Control
Treatment
3.9
7.69
P=0.5
2.7
6.8
=0.4
2.6
6.9
=0.5
a The numbers refer to the mean 24-hr proteinuria in grams at the end
of the time intervals. The P values reported are the t tests but repeat on
medians (Mann-Whitney) showed no significant difference at any time
between treatment and control group in either type.
Discussion
MPGN remains the most common type of glomerulonephritis
documented to progress to endstage renal disease in adults [4].
Donadio and Holley [6], in a controlled trial, compared a
placebo to ASA combined with dipyridamole in idiopathic
MPGN patients and did show a treatment benefit. This benefit
was statistically marginal in preservation of glomerular filtration
rate (GFR, P - 0.04) and showed no effect on proteinuria.
Zimmerman et al [31] recently reported a beneficial effect of
combined Warfarin and dipyridamole in patients with type I
MPGN. In their study, although a statistical benefit was seen in
the unpaired data relative to the reciprocal of the serum
creatinine (P < 0.025), the original trial design was a crossover
study; in the paired data analysis differences between the T and
C groups were not significant. Proteinuria was not altered by
treatment in their study by either paired or unpaired analysis.
The complication rate in that study was high with significant
hemorrhagic problems occurring in 37% of the treated patients
including one death due to intracerebral hemorrhage during
therapy. McEnery, McAdams, and West [24] and McEnery,
Fig. 3. The lack of effect of age on the rate of change in renal function
as defined by the slope of the creatinine clearance Cc. in all study
patients. Symbols are: type I MPGN: • control, 0 drug; type II
MPGN: A control, A drug.
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Fig. 4. The initial level of creatinine clearance (Cc,.) does not effect the
rate of change of renal function as defined by the slope of the Ce,..
Symbols are: type I MPGN: U control, 0 drug; type II MPGN: A
control, A drug.
West, and McAdams [32] demonstrated an improvement in
survival using longterm alternate day steroids, but the trial had
no control group, many patients were excluded from the
analysis, some patients received more therapy than prednisone
alone, and the study was restricted to children. A recent report
disputes their results and suggests that when substantial side
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Table 4. Drug complications
Major"
Timeb
months
Minor"
Type
Num-
berType
Num-
ber
Leukopenia
Alopecia
Leukopenia, hematuria
Recurrent hemoptysis
Voluntary withdrawal
2
1
1
1
1
12, 13
9
16
15
12
Infection
Hypotension
Nausea
Macroscopic
hematuria
2
3
5
1
"The trial was discontinued.
b The time after trial entry is represented.
Temporary reduction in drug therapy was made.
effects are considered steroids do not alter the overall prognosis
[25]. Kincaid-Smith's [28] study showed that coumadin,
dipyridamole, and cyclophosphamide dramatically influenced
renal survival in patients with MPGN. Her study had several
problems in interpretation including no concurrent controls and
variations relative to hypertension and/or fluid retention man-
agement. However, because of her dramatic results, we were
encouraged to examine the same medication in a prospective,
controlled trial. Kincaid-Smith [28] and McEnery, McAdams,
and West [24] both noted patients on their drug regimens who
responded dramatically within the first year of treatment. Our
results indicate this type of improvement can happen spontane-
ously (Figs. 1 and 2). Two type I and one type II C patients had
dramatic improvement with a positive slope of greater than 12
ml/min/year. We also observed the reverse with acute nephritis
apparently superimposed on biopsy-proven chronic MPGN (8
C, 4 T). This resulted in a rapid decline of previously stable
renal function. We observed an equal number of remissions
from this acute deterioration in the C group (4) as "responses"
in the T group (3) and conclude that even an acute change in a
previously stable MPGN patient does not necessarily indicate
irreversible renal failure.
Spontaneous resolution of proteinuria can oôcur [13]. Fifteen
patients in our study achieved a level of proteinuria less than
300 mg/24 hr on at least one occasion (8 C, 7 T). In only eight
was the remission prolonged (5 C, 3 T). This type of spontane-
ous change can strongly influence the interpretation of studies
where there are no or only historically control patients. Many
factors have been suggested as guides to prognosis. Cameron et
al [7] recently emphasized that patients with nephrotic range
proteinuria at the beginning or at some time within their illness
indicates a bad prognosis. Although we did not look at this
specifically, we did include degree of initial proteinuria along
with age, sex, and initial Cc. in our analysis to adjust for the
potential bias that differences in these factors between the
treatment and control group might have on the results. The lack
of significant difference in the mean slopes between the T and C
groups was not altered by these factors nor did they have any
independent prognostic significance.
In 1975, when the study was started, precise numbers re-
quired to avoid a beta error were not assessed. The 12 type II
patients entered were followed the entire 18 months. Their
complications were no greater than type I. The case accumula-
tion rate was much slower than type I, and this low number
does not allow us sufficient power to conclude anything regard-
ing the lack of effect of therapy on this type of MPGN.
However, using a standard formula for sample size [33], the
present study would allow an 80% chance at the conventional
5% level of detecting a 25% difference in the mean slope of Ccr
between the treatment and control groups in type I MPGN. We
felt that this difference was in the appropriate range considering
the potential risks of the drugs. Our results would indicate that
there is no significant benefit to this therapy on GFR or
proteinuria in type I. The prognosis in both types, however,
does not appear to be as bad as suggested by other authors [7,
13—15, 23, 28]. Our actuarial survival curves, using as an
endpoint a less than 10 mllmin, showed a type I survival of
85% at 2 years and 68% at 5 years and a type II survival of 90%
at 2 years and 70% at 5 years.
Side effects of the medication were considerable, resulting in
22% of our treatment group unable to complete the study. Many
other patients had complications of a minor nature manageable
by a reduction in dosage (Table 4). Although these complica-
tions resulted in no mortality and no significant longterm
morbidity, others [31] using a similar combination have re-
corded a higher incidence of serious hemorrhagic problems.
This drug trial suggests that any MPGN study must consider
our observed variations in the natural history before conclu-
sions regarding prognostic indicators and/or effects of medica-
tions can be reached. Certainly, we can conclude that this
therapeutic regimen is not applicable to the average patient with
type I MPGN since, in this controlled study, no significant
benefit could be observed over a period of 18 months.
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